Carbocyclic 2′,3′-didehydro-2′,3′-dideoxyguanosine (Carbovir: NSC 614846), a novel nucleoside analog, emerged as a potent and selective anti-HIV agent from a large screening program conducted by the National Cancer Institute and its contractors. Its hydrolytic stability and its ability to inhibit the infectivity and replication of HIV in T-cells at concentrations of approximately 200- to 400-fold below toxic concentrations make carbovir a top-priority candidate for development as a potential antiretroviral agent in the treatment of AIDS patients.
|Original language||English (US)|
|Number of pages||8|
|Journal||Biochemical and Biophysical Research Communications|
|State||Published - Oct 31 1988|
Bibliographical noteFunding Information:
This work was supported by NIH grant R01 CA23263, NCl contract NO1-CA-74102, and USAMRIID contract DAMD17-86-C-6013.